• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Prime Success Sends Letter to Sinovac Biotech Shareholders

    6/10/25 7:00:00 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email

    Details Why Change is Needed on Sinovac's Board in Order to Restore Company's Previous Success and Reverse Value-Destructive Path Taken Under Current Board

    Affirms Commitment to Seeing Company Reinstate Trading on the NASDAQ, Fairly Issue Dividends and Overhaul Corporate Governance

    Encourages Shareholders to Support Slate of Director Nominees Proposed by SAIF for Election at Upcoming July 8 Special Meeting

    For More Information, Visit www.SaveSinovac.com

    Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding shares, today issued a letter to shareholders in connection with the upcoming Special Meeting of Shareholders (the "Special Meeting") scheduled for July 8, 2025.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610033915/en/

    The full text of the letter can be viewed here and by visiting www.SaveSinovac.com.

    In its letter, Prime Success outlines the need for change on Sinovac's Board of Directors (the "Board") and presents key reasons to support the election of SAIF Partners IV L.P.'s ("SAIF") nominees, who are committed to taking the following value-enhancing actions:

    1. Oversee a fair, equitable, and timely distribution of cash dividends, including fully supporting the payment of the announced dividend of approximately $55 per share to all shareholders, but also actively advocating for the distribution of future dividends from the subsidiaries. Prime Success wants to ensure that the value accumulated in the Company under the management team's leadership over the years is rightfully returned to all shareholders in a timely manner.
    2. Reinstate normal trading of the Company's shares on NASDAQ and stabilize operations by resolving the uncertainty created by the current Board and taking steps to put the external auditor back on track.
    3. Overhaul governance and rebuild investor trust by adhering to corporate governance best practices, promoting greater transparency and enhancing board accountability.
    4. Lay the groundwork for sustainable long-term growth by leveraging the candidates' independence, backgrounds, and expertise to support the Company's continued development and expansion.

    Prime Success contrasts this with the current Sinovac Board members, who have:

    1. Taken actions leading to and prolonging the 2019 NASDAQ halt of trading in the Company's shares, significantly harming Sinovac's growth.
    2. Impeded the Company's ability to issue dividends over the past seven years through prolonged litigation stemming from 1Globe Capital LLC's ("1Globe") undisclosed efforts to seize board control, causing significant shareholder harm.
    3. Wasted Company resources on multiple lawsuits across various forums at the broader shareholder base's expense.
    4. Weaponized Sinovac's allocation of capital as part of their attempt to invalidate the shares of long-term investors by attempting an unjust and potentially unlawful scheme of dividend distribution.
    5. Prioritized personal interests over fiduciary obligations to all shareholders by seeking to void the Company's contractual obligations to benefit current Board members.
    6. Created significant operational uncertainty by attempting to invalidate the decisions made by the prior Board that directly led to the Company's tremendous global commercial success in the past few years, resulting in the resignation of Sinovac's external auditor.
    7. Alienated management to such a significant degree that the Sinovac management team issued an unprecedented public statement calling for a new Board election.1
    8. Appointed directors with flawed ethics through questionable and potentially unlawful procedures, resulting in disproportionate representation of investors and eroding shareholder trust.

    Prime Success shares its belief that supporting SAIF's slate is essential for the future success of Sinovac and encourages shareholders to wait for and read SAIF's proxy materials before voting for the Special Meeting on July 8, 2025.

    About Prime Success, L.P.

    Prime Success is an investment vehicle established by Advantech Capital specifically to invest in Sinovac and Sinovac Life Sciences; Advantech Capital is a private equity fund established in 2016 with a focus on innovation-driven growth opportunities in China.

    ____________________________________

    1 Press Release: SINOVAC Management Statement Regarding Auditor Resignation (April 22, 2025)

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250610033915/en/

    Media Contact

    Longacre Square Partners

    Dan Zacchei / Miller Winston

    [email protected]

    Get the next $SVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    SEC Filings

    See more
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      5/23/25 6:11:29 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      5/20/25 6:08:06 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form 6-K filed by Sinovac Biotech, Ltd.

      6-K - SINOVAC BIOTECH LTD (0001084201) (Filer)

      5/19/25 6:02:48 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINOVAC's Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders

      Intends to file definitive proxy materials in the coming days Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025 are entitled to vote at the meeting. SINOVAC's Board of Directors (the "SINOVAC Board") also issued a letter to shareholders.

      6/12/25 7:04:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims

      Affirms Support for Fair and Equitable Dividend Distribution for All Shareholders by Sinovac Corrects the Company's Misrepresentations of Vivo's Capital Contributions, Which Have Been Critical to Sinovac's Commercial Success and Ability to Return Capital to Shareholders Calls on All Shareholders to Stand up for Transparent Corporate Governance and Elect Qualified Directors to the Board at Upcoming Special Meeting on July 8 Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today sent a letter to shareholders. *** D

      6/11/25 8:30:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Prime Success Sends Letter to Sinovac Biotech Shareholders

      Details Why Change is Needed on Sinovac's Board in Order to Restore Company's Previous Success and Reverse Value-Destructive Path Taken Under Current Board Affirms Commitment to Seeing Company Reinstate Trading on the NASDAQ, Fairly Issue Dividends and Overhaul Corporate Governance Encourages Shareholders to Support Slate of Director Nominees Proposed by SAIF for Election at Upcoming July 8 Special Meeting For More Information, Visit www.SaveSinovac.com Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding

      6/10/25 7:00:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      9/12/24 4:03:46 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      6/17/24 4:02:44 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

      SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      3/20/24 7:33:23 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Financials

    Live finance-specific insights

    See more
    • SINOVAC's Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders

      Intends to file definitive proxy materials in the coming days Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025 are entitled to vote at the meeting. SINOVAC's Board of Directors (the "SINOVAC Board") also issued a letter to shareholders.

      6/12/25 7:04:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Prime Success Sends Letter to Sinovac Biotech Shareholders

      Details Why Change is Needed on Sinovac's Board in Order to Restore Company's Previous Success and Reverse Value-Destructive Path Taken Under Current Board Affirms Commitment to Seeing Company Reinstate Trading on the NASDAQ, Fairly Issue Dividends and Overhaul Corporate Governance Encourages Shareholders to Support Slate of Director Nominees Proposed by SAIF for Election at Upcoming July 8 Special Meeting For More Information, Visit www.SaveSinovac.com Prime Success L.P., (together with its affiliates, "Prime Success" or "we"), a significant shareholder of Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company") with ownership of approximately 8% of the Company's outstanding

      6/10/25 7:00:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Announces Record and Distribution Dates for Special Cash Dividend

      Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC's common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enter

      4/30/25 2:00:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company's False and Misleading Claims

      Affirms Support for Fair and Equitable Dividend Distribution for All Shareholders by Sinovac Corrects the Company's Misrepresentations of Vivo's Capital Contributions, Which Have Been Critical to Sinovac's Commercial Success and Ability to Return Capital to Shareholders Calls on All Shareholders to Stand up for Transparent Corporate Governance and Elect Qualified Directors to the Board at Upcoming Special Meeting on July 8 Vivo Capital ("Vivo" or "we"), a leading global investment firm focused exclusively on healthcare and life sciences and an approximately 8% shareholder in Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), today sent a letter to shareholders. *** D

      6/11/25 8:30:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading

      BOSTON, March 20, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac") shareholder Heng Ren Partners, LLC funds ("Heng Ren") today sent an open letter to Sinovac's shareholders outlining the significant and decisive action that Sinovac's Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac's Board of Directors announce a distribution of $8.9 billion in cash to its shareholders and cause the resumption of trading of the Company's shares. The full text of the letter follows: March 20, 2025 Dear Fellow Sinovac Shareholders: Like you, we are shareholders in Sinovac Biotech Ltd. ("Sinovac" or the "Company").

      3/20/25 11:05:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care